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Abstract 
Background: The therapeutic effect of aminoglycosides is highest and optimal when the peak plasma concentra-
tion (Cmax)/minimal inhibitory concentration (MIC) ratio is between 8 and 10. The French guidelines recommend to 
use high doses of aminoglycosides for empiric antibiotic therapy in patients suffering from severe sepsis or septic 
shock. In clinical practice, the recommended target is an amikacin Cmax between 60 and 80 mg/L, which corresponds 
to approximately 8 times the MIC breakpoint, as defined by the European Committee on Antimicrobial Susceptibil-
ity Testing. The aim of this study was to assess the incidence and impact on mortality of an amikacin concentration 
between 60 and 80 mg/L in patients suffering from severe sepsis or septic shock.
Methods: This was a prospective observational cohort study conducted in two intensive care units (ICU). Patients 
receiving amikacin at a loading dose of 30 mg/kg for severe sepsis or septic shock were enrolled in the cohort. 
The target Cmax for amikacin was between 60 and 80 mg/L, as recommended by French guidelines (i.e. Cmax/MIC 
breakpoint = 8–10).
Results: Over the study period, the amikacin Cmax was <60 mg/L, between 60 and 80 mg/L, and >80 mg/L in 20 
(18.2%), 46 (41.8%) and 44 (40%) of the 110 selected patients, respectively. Mortality rate was 40, 28.3 and 56.8% in 
the groups of patients with Cmax < 60 mg/L, 60 mg/L < Cmax < 80 mg/L and Cmax > 80 mg/L, respectively. Following 
multivariate analysis, mortality rate was significantly lower in the group of patients with amikacin Cmax between 60 
and 80 mg/L than in the group of patients with amikacin Cmax > 80 mg/L (P = 0.004). The multivariate analysis also 
revealed that the factors independently associated with a higher in-ICU mortality rate were age (P = 0.02) and norepi-
nephrine dose (P = 0.0001).
Conclusions: With a loading dose of 30 mg/kg of amikacin, concentration was potentially suboptimal 
(Cmax < 60 mg/L) in only 18.2% of patients. The pharmacodynamic target (60 mg/L < Cmax < 80 mg/L) recommended 
by French guidelines was reached in 41.8% of patients and was associated with reduced in-ICU mortality. But amika-
cin overexposure (i.e. Cmax > 80 mg/L) was frequent and potentially associated with increased mortality.
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Background
The usefulness of antimicrobial combination therapy, 
such as the use of aminoglycosides in patients with severe 
sepsis or septic shock, remains controversial [1, 2]. Nev-
ertheless, early and appropriate antimicrobial therapy 
in septic shock patients has been reported to reduce in-
hospital mortality [2]. In view of this, aminoglycosides 
are often combined with another antibiotic in patients 
with severe sepsis or septic shock in order to broaden 
the treatment’s spectrum of activity and obtain bacteri-
cidal synergy. The therapeutic effect of aminoglycosides 
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is highest and optimal when the peak plasma concen-
tration (Cmax)/minimal inhibitory concentration (MIC) 
ratio is between 8 and 10 [3]. However, in patients with 
severe sepsis or septic shock, aminoglycosides are fre-
quently used in empiric antimicrobial treatment without 
the causal micro-organisms and their MICs being identi-
fied. The French guidelines recommend to use high doses 
of aminoglycosides for empiric antibiotic therapy in 
patients suffering from severe sepsis or septic shock, and, 
specifically, doses of 25–30 mg/kg in the case of amikacin 
[4, 5]. In clinical practice, the recommended target is an 
amikacin Cmax between 60 and 80 mg/L [4], which corre-
sponds to approximately 8–10 times the MIC breakpoint, 
as defined by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) of Pseudomonas aerugi-
nosa and Enterobacteriaceae [5]. Previous studies have 
shown that a loading dose of 25 mg/kg frequently leads 
to a suboptimal amikacin Cmax (>30% of patients with 
Cmax < 60 mg/L) [6, 7], prompting an increase in the load-
ing dose to 30 mg/kg without improving outcomes [8, 9]. 
Yet the dose of 30 mg/kg has been evaluated in a limited 
number of patients (n < 50) [8, 9]. The aim of this study 
was to assess the incidence and impact on mortality of 
an amikacin concentration between 60 and 80  mg/L in 
patients suffering from severe sepsis or septic shock.
Methods
The present observational study was approved by the 
Ethics Committee of Félix Guyon University Hospital 
(R15003). The requirement to obtain written informed 
consent from patients was waived, as the study was non-
interventional and followed our usual protocol. However, 
all patients or their legally authorised representative was 
verbally informed about the process of data collection 
and could refuse to participate.
The reporting of this study complies with the Strength-
ening the Reporting of Observational studies in Epidemi-
ology recommendations statement [10].
Selection of the study sample
This prospective observational cohort study was con-
ducted from April 2015 to December 2015 in one mixed 
medical/surgical ICU and in one surgical ICU at two 
French university hospitals.
All patients were over 18  years old and treated for 
severe sepsis or septic shock with a combination therapy 
of amikacin at a loading dose of 30 mg/kg (±2.5 mg/kg) 
on the day of enrolment.
The first dose of amikacin was calculated using the 
total body weight of the day for patients with a body mass 
index <30  kg/m2. For patients with a body mass index 
≥30  kg/m2, the dose was calculated using the adjusted 
body weight, which was calculated as follows: ideal body 
weight (height (cm)  −  100  −  [height (cm)  −  150]/4 
for male gender and height (cm)  −  100  −  [height 
(cm) − 150]/2 for female gender) + 0.4 [total body weight 
at admission-ideal body weight].
Severe sepsis and septic shock were defined following 
the Surviving Sepsis Campaign guidelines [11].
Only the first day of amikacin administration was 
studied.
The prescribed duration of the continuous infusion was 
30 min. Measurements of Cmax and trough concentration 
were taken 30 min and 24 h after the end of infusion. All 
samples were analysed immediately. Amikacin dosages 
were measured using a fluorescence polarisation immu-
noassay [12].
Trough concentration was considered elevated if 
>2.5  mg/L and was assessed only if treatment length 
was >5 days or in cases of renal insufficiency, as recom-
mended by French guidelines [4, 6].
The exclusion criteria were: treatment with amikacin 
within 7  days prior to inclusion; inappropriate dose of 
amikacin (<27.5 or >32.5 mg/kg); inappropriate duration 
of amikacin infusion (<25 or >35 min); and inappropriate 
delays in measuring the amikacin Cmax (<20 or >40 min 
after the end of infusion).
Data collected and study endpoint
Patient comorbidities at ICU admission were recorded 
on inclusion.
After administering the loading dose of 30  mg/kg of 
amikacin, the main endpoint was to evaluate the impact 
of the amikacin Cmax on the in-ICU mortality of patients 
with severe sepsis or septic shock.
Statistical analysis
Results were expressed as total number (percentage) for 
categorical variables and as median [25th–75th percen-
tiles] for continuous variables. Continuous variables were 
compared using the Mann–Whitney test or the Kruskal–
Wallis test, as appropriate. Categorical variables were 
compared using the Chi-square test or the Fisher’s exact 
test, as appropriate. Risk factors for in-ICU mortality in 
bivariate analysis with P < 0.1 were entered into a multi-
variate logistic regression analysis using backward selec-
tion with P < 0.05.
We considered that 50 patients were needed in the 
non-survivors group to perform a multivariate analysis 
with ten variables [13]. Based on an in-ICU mortality rate 
of 50% in patients with severe sepsis or septic shock [6], 
we calculated that 100 patients had to be included in the 
study cohort for there to be a minimum of 50 patients 
in the non-survivors group. Collinearity between inde-
pendent factors was investigated. When identified, the 
most clinically relevant factor was chosen for use in the 
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multivariate model. A P value <0.05 was considered sig-
nificant. Analyses were performed using SAS statistical 
software (8.2, Cary, NC, USA).
Results
Study population
Over the study period, 921 patients were hospitalised, of 
which 150 (16.3%) received amikacin for severe sepsis or 
septic shock. Among the latter, 40 were excluded: 15 had 
received aminoglycosides in the previous seven days; 15 
had received an inappropriate dose of amikacin; and 10 
had an incorrect Cmax measurement taken. The remain-
ing 110 patients formed the cohort.
Patient characteristics on ICU admission and study 
inclusion are shown in Tables 1, 2 and 3.
The median age was 61 [51–70], the median Simpli-
fied Acute Physiology Score 2 at admission was 54 [41–
68], and the median SOFA score on the day of amikacin 
administration was 10 [8–11]. The sources of infection 
were respiratory in 57 cases (51.8%), intra-abdominal in 
16 cases (14.5%) and catheter related in 9 cases (8.2%). 
Bacteraemia was present in 32 cases (29.1%) (Table 3).
The most frequently isolated bacteria were P. aerugi-
nosa (19.1%), Enterobacter spp. (16.7%) and Escherichia 
coli (13.9%) (Table 3).
Amikacin dosages
The median dose of amikacin was 30 [29.2–30.6] mg/kg. 
Pharmacodynamic amikacin targets (60  mg/L  <  Cmax  <   
80  mg/L) were achieved in 46 of the 110 patients 
(41.8%). Forty-four of the 110 patients (40%) had a 
Cmax > 80 mg/L, and 20 of the 110 patients (18.2%) had 
a Cmax  <  60  mg/L. No patient had a Cmax  <  30  mg/L 
(Table 4).
Trough concentration was measured for 65 patients 
(68.2%). Among these, 51 (78.5%) had a trough concen-
tration >2.5 mg/L.
Prognosis
The in-ICU mortality rate was 41.8%. A univariate anal-
ysis revealed that the amikacin Cmax was not associated 
with a reduction in the in-ICU mortality rate (Cmax was 
73.6 [65.9–83.6] mg/L in survivors and 81.9 [66.5–89.7] 
mg/L in non-survivors, P = 0.12).
The univariate analysis also showed that the in-ICU 
mortality rate was lower in the group of patients with a 
Cmax between 60 and 80  mg/L (28.3%) than in patients 
with a Cmax > 80 mg/L (56.8%, P = 0.006).
Moreover, there was no statistically significant differ-
ence of mortality between the group of patients with a 
Cmax between 60 and 80 mg/L and the group of patients 
with a Cmax < 60 mg/L (40%, P = 0.18).
The univariate analysis of trough concentration meas-
urements in 75 of the 110 patients (68.2%) revealed that a 
higher amikacin trough concentration was not associated 
with a higher in-ICU mortality rate (5.2 [2.3–10.4] mg/L 
in survivors versus 8.6 [4.2–14.3] mg/L in non-survivors, 
P = 0.058).
The proportion of micro-organisms with a greater than 
usual amikacin MIC (i.e. non-fermenting Gram-negative 
bacilli) in non-survivors was similar to that in survivors 
(16 of 64 in survivors group versus 6 out of 46 in non-
survivors group, P = 0.12).
The other risk factors found to be predictive of in-ICU 
mortality (based on a bivariate analysis with P < 0.1) are 
exposed in Table 2.
Following multivariate analysis, compared to a Cmax 
between 60 and 80  mg/L, Cmax  >  80  mg/L was associ-
ated with a higher probability of mortality (OR 95% CI 
3.96 [1.54–10.2], P = 0.004), and Cmax < 60 mg/L was not 
associated with a higher probability of mortality (OR 95% 
CI 1.92 [0.46–8.24], P  =  0.4). The multivariate analysis 
also revealed that the factors independently associated 
with a higher mortality rate were a higher age (P = 0.02) 
and a higher norepinephrine dose (P = 0.0001) (Table 5).
In survivors, acute kidney injury was not associated 
with a Cmax > 80 mg/L (15.8% of patients who developed 
acute kidney injury had a Cmax  >  80  mg/L, while 14.2% 
who did not had a Cmax > 80 mg/L, P = 0.88).
An amikacin trough concentration >2.5  mg/L was 
not significantly associated with acute kidney injury 
(P = 0.26).
Discussion
To our knowledge, this is the largest study evaluating the 
incidence and impact on in-ICU mortality of an ami-
kacin Cmax achieved with a high loading dose of 30 mg/
kg. Roger et al. and Galvez et al. evaluated the effects of 
a dose of 30  mg/kg of amikacin in 47 and 33 patients, 
respectively, but did not assess the impact of amikacin 
concentration on mortality [8, 9]. In these studies, the 
median Cmax obtained with a loading dose of 30  mg/kg 
of amikacin was 75 mg/L. This is consistent with previ-
ous studies that reported values ranging from 72.1 to 
75.8 mg/L [8, 9]. We found that, with a loading dose of 
30 mg/kg of amikacin, the pharmacodynamic Cmax target 
(i.e. >60 mg/L for the less susceptible bacteria) was fre-
quently achieved (81.2% cases), a rate that is consistent 
with previous studies [8, 9].
Studies by Taccone et al. [7] and de Montmollin et al. 
[6], in which amikacin concentration following a load-
ing dose of 25  mg/kg was evaluated, found a high fre-
quency of underdosing (>30%). These results prompted 
an increase in the loading dose of amikacin with the aim 
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of achieving a Cmax > 60 mg/L in the highest number of 
patients [8, 9].
In our study, the amikacin Cmax between 60 and 
80  mg/L recommended by French guidelines [4] was 
associated with a reduction in the in-ICU mortality rate. 
In theory, a Cmax of amikacin between 60 and 80  mg/L 
would be optimal for treating sepsis caused by less sus-
ceptible Enterobacteriaceae and non-fermenting Gram-
negative bacterial infections (such as P. aeruginosa) 
with a MIC of 8 mg/L. This is highlighted in a study by 
Dubois et al. [14], in which 61% of the isolated P. aerugi-
nosa strains had a MIC of 8 mg/L. However, in patients 
with severe sepsis or septic shock, aminoglycosides are 
frequently used in empiric antimicrobial treatment with-
out the causal micro-organisms and their MICs being 
identified. One of the major potential advantages of 
using aminoglycoside combination therapy is to broaden 
antibiotic treatment in cases of resistant bacteria, which 
may be found in ICUs [15, 16]. Combination therapy can 
increase the success of empiric therapy in up to 20% of 
Table 1 Baseline patient characteristics at intensive care unit admission and at inclusion
Results are expressed as the median [25th–75th percentiles] or n (%) as appropriate
APACHE Acute Physiology and Chronic Health Evaluation, Cmax peak plasma concentration, PaO2/FiO2 partial pressure of oxygen in arterial blood/fraction of inspired 
oxygen
Characteristics Total (n = 110) Amikacin Cmax (mg/L) P
<60 (n = 20) 60–80 (n = 46) >80 (n = 44)
At ICU admission
 Age (years old) 61 [51–70] 57. 5 [50.5–69] 63 [45–69] 62 [55.5–70] 0.521
 Male sex 78 (70.9) 14 (70) 33 (71.7) 31 (70.5) 0.986
 Weight (kg) 70 [58.2–80] 60 [52.5–73.5] 70 [58.2–80] 72.5 [65–82] 0.029
 Body mass index (kg/m2) 24.6 [20.7–28] 21.1 [18.5–25.7] 23.7 [20.8–27.3] 26.6 [21.9–29] 0.023
 APACHE II 23 [18–28] 25 [21–28] 23 [17–28] 22 [18–26] 0.309
 Simplified Acute Physiology Score 2 54 [41–68] 62 [47–70] 54 [44–63] 52 [40–67] 0.361
 History of congestive heart failure 12 (10.9) 1 (5) 8 (17.4) 3 (6.9) 0.177
 Liver cirrhosis 4 (3.6) 0 2 (4.3) 2 (4.5) 0.63
 Chronic obstructive pulmonary disease 26 (23.6) 5 (25) 10 (21.7) 11 (25) 0.924
 Chronic kidney disease requiring dialysis 9 (8.2) 1 (5) 2 (4.3) 6 (13.6) 0.233
 Cancer (<3 months) 16 (14.5) 4 (20) 10 (21.7) 2 (4.5) 0.051
 Diabetes mellitus 39 (35.5) 7 (35) 12 (26.1) 20 (45.5) 0.158
 Immunodepression 24 (21.8) 6 (30) 9 (19.6) 9 (20.5) 0.616
At the day of aminoglycoside administration
 Day since admission 1 [0–5] 1 [0–6] 0.5 [0–5] 1.5 [0–6.5] 0.834
 Emergent surgery 25 (22.7) 9 (45) 12 (26.1) 4 (9.1) 0.005
 Sequential Organ Failure Assessment score 10 [8–11] 10 [9–11] 10 [7–12] 10 [8–12] 0.950
 Weight (kg) 70 [60–80] 66 [55.5–79] 71 [58.2–80] 72 [65.5–82] 0.104
 Weight gain since ICU admission (kg) 0 [0–3] 0 [0–3] 0 [0–2] 0 [0–2] 0.847
 Extracorporeal membrane oxygenation 15 (13.6) 4 (20) 5 (10.9) 6 (13.6) 0.611
 Catecholamines 89 (80.9) 16 (80) 36 (78.3) 37 (84.1) 0.776
 Norepinephrine (µg/kg/min) 0.44 [0.1–0.93] 0.88 [0.11–1.64] 0.46 [0.09–0.83] 0.41 [0.11–0.81] 0.343
 PaO2/FiO2 ratio 177 [122–264] 155 [90–230] 203 [140–289] 159 [118–258] 0.234
 Renal replacement therapy 40 (36.4) 12 (60) 15 (32.6) 13 (29.5) 0.05
 Glomerular filtration rate (mL/min) 45 [18.6–86.2] 22.1 [0–90.4] 43.6 [24.6–86] 49.7 [22.5–83.9] 0.583
 Lactate level (mmol/L) 2.3 [1.2–4] 2.7 [1.5–4] 2.3 [1.2–6.5] 1.7 [1.2–3.2] 0.315
 Platelet count (G/L) 204 [97–307] 170 [84–218] 204 [90–340] 230 [141–325] 0.113
 Hematocrit level (%) 29.3 [26–31.6] 30.3 [26.8–32.7] 29.7 [27.3–31.6] 27.7 [25.3–31.1] 0.284
 Leucocyte count (G/L) 13.9 [8.9–21] 14.1 [7.1–17.7] 15.6 [8.9–23.2] 13 [9.2–20.3] 0.373
 Glasgow Coma Scale score 15 [13–15] 15 [13–15] 15 [13–15] 15 [13–15] 0.661
 Bilirubin level (mg/dL) 12 [8–20] 12.5 [9–20] 12 [9–29] 12 [7–19] 0.657
 Prothrombin time (%) 66 [52–78] 66 [57–78] 64 [47–81] 67 [57–78] 0.606
 Proteinemia (g/L) 56 [47–63] 46.5 [40.5–60.5] 55.5 [49–64] 59 [51–64.5] 0.007
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patients [17, 18]. A high Cmax is therefore likely necessary 
given that P. aeruginosa is one of the most frequently iso-
lated micro-organisms, even in cases of early-onset sepsis 
[19, 20].
We agree with Roger et  al. [8] that a lower amikacin 
Cmax may be enough to treat sepsis. In their study, all iso-
lated strains had an amikacin MIC  ≤  4  mg/L, meaning 
that a Cmax between 32 and 64 mg/L would be sufficient 
to meet pharmacokinetic/pharmacodynamic parameters 
in all patients (i.e. Cmax/MIC > 8) [8]. In the present study, 
we found that with a high dose of 30 mg/kg of amikacin, 
Cmax  >  80  mg/L was frequently observed and was asso-
ciated with higher mortality rates. We did not identify 
a clear hypothesis to explain the relationship between 
amikacin concentration >80  mg/L and mortality. Similar 
mortality results were found in a small randomised study 
of 99 patients by Galvez et al. [9] compared three dosing 
regimens (15, 25 and 30  mg/kg) of amikacin in patients 
with severe sepsis or septic shock. In the 15, 25 and 
30 mg/kg amikacin-treated groups, the study found that a 
Table 2 Baseline patient characteristics at intensive care unit admission and at inclusion (survivors/non-survivors)
Results are expressed as the median [25th–75th percentiles] or n (%) as appropriate
APACHE Acute Physiology and Chronic Health Evaluation, Cmax peak plasma concentration, PaO2/FiO2 partial pressure of oxygen in arterial blood/fraction of inspired 
oxygen
Characteristics Survivors (n = 64) Non-survivors (n = 46) P
At ICU admission
 Age (years old) 60 [45–69] 63 [57–73] 0.03
 Male sex 49 (76.6) 29 (63) 0.12
 Weight (kg) 70 [60–80] 70 [58–79] 0.84
 Body mass index (kg/m2) 24.6 [20.7–27.8] 24.4 [20.7–28] 0.58
 APACHE II 21 [17–25] 26 [22–29] 0.0007
 Simplified Acute Physiology Score 2 52 [41–60] 57 [45–73] 0.05
 History of congestive heart failure 6 (9.4) 6 (13) 0.54
 Liver cirrhosis 0 4 (8.7) 0.03
 Chronic obstructive pulmonary disease 15 (23.4) 11 (23.9) 0.96
 Chronic kidney disease requiring dialysis 4 (6.3) 5 (10.9) 0.38
 Cancer (<3 months) 11 (17.2) 5 (10.9) 0.35
 Diabetes mellitus 15 (23.4) 24 (52.2) 0.002
 Immunodepression 16 (25) 8 (17.4) 0.34
At the day of aminoglycoside administration
 Day since admission 1 [0–5] 2 [0–7] 0.32
 Emergent surgery 17 (26.6) 8 (17.4) 0.26
 Sequential Organ Failure Assessment score 9 [7–10] 10 [9–13] 0.004
 Weight (kg) 70 [60–81] 70.5 [60–80] 0.92
 Weight gain since ICU admission (kg) 0 [0–2] 0 [0–3] 0.62
 Extracorporeal membrane oxygenation 7 (10.9) 8 (17.4) 0.33
 Catecholamines 49 (76.6) 40 (87) 0.17
 Norepinephrine (µg/kg/min) 0.26 [0.04–0.61] 0.83 [0.41–1.65] 0.0002
 PaO2/FiO2 ratio 200 [140–280] 147 [103–259] 0.06
 Renal replacement therapy 19 (29.7) 21 (45.7) 0.09
 Glomerular filtration rate (mL/min) 53.5 [29.7–90.4] 29.8 [0–65.9] 0.008
 Lactate level (mmol/L) 1.7 [1.2–3.1] 3.2 [1.4–7] 0.01
 Platelet count (G/L) 205 [105–339] 201 [86–270] 0.47
 Hematocrit level (%) 29.2 [26–31.3] 29.7 [26–32.4] 0.54
 Leucocyte count (G/L) 15.6 [9.4–22.3] 13.4 [7.8–18.7] 0.22
 Glasgow Coma Scale score 15 [14, 15] 15 [12–15] 0.23
 Bilirubin level (mg/dL) 12 [8–17] 145 [9–26] 0.22
 Prothrombin time (%) 72 [57–81] 60 [47–75] 0.01
 Proteinemia (g/L) 58 [49–64] 52 [46–62] 0.1
 Amikacin Cmax between 60 and 80 mg/L 34 (53.1) 13 (28.3) 0.009
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Cmax > 60 mg/L was reached in 0, 39 and 76% of patients, 
respectively, but the mortality rate was 0, 9.1 and 22.2%, 
respectively. This study was not, however, designed to sta-
tistically analyse mortality. We found that patients with 
amikacin overexposures tended to have greater amikacin 
trough concentrations (P = 0.08). It is well established that 
aminoglycosides are associated with nephrotoxicity [21, 
22], and that a high amikacin Cmax in ICU is associated 
with higher trough-level concentrations [6]. Nevertheless, 
it is difficult to consider these high Cmax as “overexposure” 
and further studies are needed. Moreover, recent in vitro 
and in  vivo studies suggest that higher aminoglycosides 
exposure should be targeted for difficult to treat pathogens 
[23, 24]. To date, there is a lack of data on aminoglycoside-
related toxicity in once-daily dose and short-duration ami-
noglycoside therapy. The present study was not designed 
to analyse and evaluate the association between acute kid-
ney injury and trough concentration or aminoglycoside 
Cmax, in that trough concentrations were not measured 
in all patients, as suggested by French guidelines [4]. Fur-
thermore, previous studies suggest that aminoglycoside-
associated acute kidney injury cannot be solely attributed 
to aminoglycosides, because other factors are frequently 
associated with acute kidney injury in the ICU, including 
sepsis, septic shock or nephrotoxic drugs [25, 26].
Despite the current trend to increase doses of antibiot-
ics in ICUs for pharmacokinetic/pharmacodynamic pur-
poses, no beneficial effect on outcome has been clearly 
demonstrated [6–8]. In clinical practice, in Europe phy-
sicians are still using low doses of aminoglycosides, as 
shown by a recent survey of antimicrobial prescribing 
practices in ICUs, where aminoglycosides were adminis-
tered at “low” doses (5 mg/kg for gentamicin and 15 mg/
kg for amikacin) [27].
Table 3 Sites of infection and isolated micro-organisms
N




 Skin and soft tissue 6






 Staphylococcus aureus 13
 Other staphylococci 3
 Enterococcus spp. 5
 Streptococcus spp. 3
Bacilli 84
 Enterobacteriaceae 56
 Escherichia coli 15
 Enterobacter spp. 18
 Serratia marcescens 3
 Klebsiella spp. 14
 Other Enterobacteriaceae 6
 Pseudomonas aeruginosa 21
 Acinetobacter baumannii 2
 Other bacilli 5
None 36
Table 4 Amikacin pharmacokinetic/pharmacodynamic par-
ameters
Results are expressed as the median [25th–75th percentiles] or n (%)
a Trough concentration was not measured for 45 patients
Variable n = 110
Dose (mg) 2100 [1800–2400]
Dose (mg/kg) 30 [29.2–30.6]
Peak plasma concentration (mg/L) 75 [66.1–86.1]
Patients with a peak concentration >80 mg/L 44 (40)
Patients with a peak concentration between 60 and 
80 mg/L
46 (41.8)
Patients with a peak concentration <60 mg/L 20 (18.2)
Patients with a peak concentration <30 mg/L 0
Trough concentration >2.5 mg/La 51 (78.5)
Table 5 Multivariate analysis of  risk factors for  in-inten-
sive care unit mortality
The Hosmer–Lemeshow goodness-of-fit test P value was 0.248. The Nagelkerke 
and Cox/Snell R2 were, respectively, 0.347 and 0.258
CI confidence intervals, Cmax peak plasma concentration, PaO2/FiO2 partial O2 
pressure in arterial blood/fraction of the inspired oxygen ratio, SOFA Sequential 
Organ Failure Assessment
Variables Adjusted odds  
ratio (CI 95%)
P value





 Between 60 and 80 mg/L Reference Reference
 <60 mg/L 1.92 (0.46–8.24) 0.4
 >80 mg/L 3.96 (1.54–10.2) 0.004
Prothrombin time 0.98 (0.96–1.01) 0.118
PaO2/FiO2 ratio 0.99 (0.99–1) 0.28
Diabetes mellitus 1.6 (0.59–4.38) 0.32
Glomerular filtration rate (mL/
min)
0.99 (0.98–1.01) 0.43
Lactate level 1.01 (0.89–1.14) 0.53
SOFA 1.03 (0.81–1.3) 0.18
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This study has severe limitations. Given that it was not 
a randomised controlled trial comparing different load-
ing regimens, we cannot conclude a direct causal rela-
tionship between the amikacin Cmax and the mortality 
rate. We did not evaluate the subsequent amikacin Cmax 
after the first injection of the study, and MIC of isolated 
bacteria was not determined for amikacin. Although the 
study population may be considered small, to our knowl-
edge this is the largest cohort to have been selected for 
evaluating the impact of high doses of 30 mg/kg of ami-
kacin in patients with severe sepsis or septic shock [8, 
9]; moreover, other studies confined their analysis to 
pharmacokinetics/pharmacodynamics parameters [8, 9]. 
We agree that analysing pharmacokinetics/pharmaco-
dynamics parameters of medications is one of the first 
steps before launching an impact study [28]. Neverthe-
less, aminoglycosides are associated with well-known 
and severe side effects and analysing outcomes when 
increasing usual doses is indispensable. Previous stud-
ies reported that when high doses of aminoglycosides 
are administered, sampling within 90 min of the infusion 
provides information that leads to the overestimation 
of the peak serum concentration/minimum inhibitory 
concentration ratio and to the inaccurate calculation of 
pharmacokinetic parameters [29, 30]. Nevertheless, these 
studies were confined to gentamicin concentrations in a 
limited number of healthy volunteers (<13) [29, 30]. By 
contrast, recent studies [6–10] have reported measure-
ments of amikacin Cmax performed 30 min after infusion, 
as suggested by French guidelines [4].
Conclusion
This study suggests that with a high loading dose of 
30  mg/kg the amikacin Cmax between 60 and 80  mg/L 
recommended by French guidelines is associated with 
reduced in-hospital mortality, but that it is difficult to 
achieve in ICU patients (<50%). Amikacin overexposure 
(i.e. Cmax > 80 mg/L) was frequent and potentially associ-
ated with increased mortality.
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